Table 1.
Characteristics of patients included in the de novo cardiac event component
| Treatment group, (N) | Age1, mean (SD) | Ferritin2, mean (SD), median (IQR) | Gender3: males, n (%) |
|---|---|---|---|
| DFO (343) | 21.2 (6.9) | 2500 (1653), 2014 (1322–3231) | 176 (51.3) |
| DFP (97) | 25.3 (6.8) | 2903 (2003), 2453 (1297–4330) | 46 (47.4) |
| Combination (166) | 26.7 (6.0) | 2551 (1795), 2007 (1206–3678) | 79 (47.6) |
| DFX (118) | 26.0 (8.7) | 2673 (1765), 2076 (1284–3718) | 45 (38.1) |
IQR, interquartile range; DFO, desferrioxamine; DFP, deferiprone; DFX, deferasirox.
1
anova: F-test = 31.3, P < 0.001. Significant comparisons DFP vs. DFO, Combination vs. DFO, DFX vs. DFO (all P-values <0.001 were statistically significant considering 0.05/6 = 0.008 as the confidence level after the Bonferroni correction).
2
anova: F-test = 1.4, P = 0.23.
3
Fisher’s exact test: P = 0.10.